[1] 王国栋,党亚正.肝癌血浆EGFR水平与放疗效果关系研究.现代肿瘤医学,2015,23: 247-249.
[2] Bae SH, Kim MS, Jang WI,et al. Low Hepatic Toxicity in Primary and Metastatic Liver Cancers after Stereotactic Ablative Radiotherapy Using 3 Fractions..J Korean Med Sci, 2015, 30: 1055-1061.
[3] 刘立国,吴健雄,荣维淇, 等. 中央型肝癌手术切除联合放疗的临床研究.中华肝胆外科杂志,2013,19: 340-342.
[4] 田慧,和振坤,徐庆杰,等.TACE联合放疗治疗原发性肝癌的疗效及对生存质量的影响.中国老年学杂志,2013,33: 4987-4989.
[5] Li GZ, Liang HF, Liao B, et al. PX-12 inhibits the growth of hepatocelluar carcinoma by inducing S-phase arrest, ROS-dependent apoptosis and enhances 5-FU cytotoxicity..Am J Transl Res, 2015, 7: 1528-1540.
[6] Kim SH, Park YN, Lim JH,et al. Characteristics of combined hepatocelluar cholangiocarcinoma and comparison with intrahepatic cholangiocarcinoma..Eur J Surg Oncol, 2014, 40: 976-981.
[7] 刘晓洪,章阳,王越华,等.低分割放疗对肝癌患者细胞免疫功能的影响.安徽医药,2015: 745-746.
[8] 艾宁,冀宏.TACE联合放疗治疗原发性肝癌的临床疗效.中国老年学杂志,2015: 6144-6146.
[9] Cai K, Yang R, Chen H,et al. Simulation and Visualization of Liver Cancer Ablation Focus in Optical Surgical Navigation..J Med Syst, 2016, 40: 19.
[10] 尹卫华,胡小雄,范惠珍,等.不同剂量三氧化二砷静滴联合适形放疗治疗中晚期原发性肝癌.山东医药,2014,54: 32-34.
[11] 谢丽,尹震宇,魏嘉,等.血浆EGFR19外显子缺失突变高灵敏度检测技术的建立.临床肿瘤学杂志,2014,19: 407-410.
[12] Zhang N, Chen H, Liu AY,et al. Gold conjugate-based liposomes with hybrid cluster bomb structure for liver cancer therapy..Biomaterials, 2016, 74: 280-291.
[13] 张孔志,余文昌,陈示光,等.TACE 联合放疗对原发性肝癌合并门静脉癌栓患者生存的影响.中国肿瘤临床,2012,39: 35-37.
[14] 姚晖,龚金兰,李莉,等.肝癌患者精确放疗后 HBV 病毒再激活的危险因素分析.实用癌症杂志,2014: 675-677.
[15] Huang YQ, Lu X, Min H, et al. Green tea and liver cancer risk: A meta-analysis of prospective cohort studies in Asian populations. Nutrition, 2016, 32: 3-8.
[16] 黄伟,卢彦达,张炜,等. 原发性肝癌精确放疗致乙型肝炎病毒再激活分析.中华放射肿瘤学杂志,2013,22: 193-197.
[17] Xing M, Lahti S, Kokabi N,et al. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival. Clin Nucl Med, 2016, 41: 21-27. |
